Proton therapy kills cancer cells by delivering proton beams to the tumour. Opposite to conventional radiation therapy, proton beams deposit their maximum energy within a precisely defined range, known as the Bragg peak. Owing to the finite range, the integral dose of a proton treatment is lower than in conventional therapy.
Ion beam applications (IBA) the market leader in PT, has designed and equipped the majority of clinically operating proton therapy centres around the world. To date, over 20 IBA proton centres are already operational or at various stages of development.
Université catholique de Louvain (UCL) is Belgium's largest French speaking University. UCL educates around 30.000 students from 127 nationalities that span 5 continents. A center of excellence in science, UCL consists of 15 faculties and institutes that offer supervision to 1800 PhD students.
UCL and IBA are reinforcing their long-standing collaboration by founding a new research unit, called imagX.R.The research unit is composed of the UCL’s IC-TEAM group on the Louvain-La-Neuve campus, the UCL’s MIRO group at the St Luc hospital in Brussels, and the research group of IBA. The collaboration successfully researched and engineered in room imaging solutions that are now sold as products to IBA’s clients.
imagX.R is a multi-disciplinary team with competences in medical physics, signal processing, radiation oncology, and software development. The research environment provides a smooth connection between academic and industrial research. Links with IBA treatment centres ensure close contact with the clinical world. Aiming to develop advanced solution for image and dose guided proton therapy our research is directed along two main axes: